Cargando…

The risk of obesity and the association of body mass index on all-cause mortality after cardiac resynchronization therapy

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public grant(s) – EU funding. Main funding source(s): European Union. BACKGROUND: Overweight and obese people have a higher risk of acquiring heart failure, however these patients tend to have more favorable outcome, a phenomenon known as the obesit...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkel, E D, Behon, A, Schwertner, W R, Kuthi, L, Veres, B, Masszi, R, Osztheimer, I, Papp, R, Molnar, L, Zima, E, Geller, L, Kosztin, A, Merkely, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207426/
http://dx.doi.org/10.1093/europace/euad122.453
_version_ 1785046450749571072
author Merkel, E D
Behon, A
Schwertner, W R
Kuthi, L
Veres, B
Masszi, R
Osztheimer, I
Papp, R
Molnar, L
Zima, E
Geller, L
Kosztin, A
Merkely, B
author_facet Merkel, E D
Behon, A
Schwertner, W R
Kuthi, L
Veres, B
Masszi, R
Osztheimer, I
Papp, R
Molnar, L
Zima, E
Geller, L
Kosztin, A
Merkely, B
author_sort Merkel, E D
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public grant(s) – EU funding. Main funding source(s): European Union. BACKGROUND: Overweight and obese people have a higher risk of acquiring heart failure, however these patients tend to have more favorable outcome, a phenomenon known as the obesity paradox. PURPOSE: We aimed to investigate the risk of obesity and the association of body mass index (BMI) on all-cause mortality in heart failure CRT patients at long-term. METHODS: We examined retrospectively 1585 patients undergoing CRT implantation at our clinic between 2000-2020 with their BMI available at baseline. Patients were sorted into three groups: normal weight (BMI ‹25), overweight (BMI 25-29.9) and obese (BMI≥30). The composite primary endpoint was all-cause mortality, heart transplantation or implantation of a left ventricular assist device. Time-to-event data was studied by log-rank and multivariate Cox regression analysis. We studied peri-procedural complication rates, and reverse remodeling, defined as a ≥15% relative increase in left ventricular ejection fraction (LVEF) within 6 months after CRT implantation. RESULTS: During our mean follow-up time of 5.1 years, 973 (61%) reached our primary endpoint, 302 (66%) in the BMI ‹25 group, 389 (61%) in the BMI 25-29.9 group and 282 (58%) in the BMI≥30 group. Obese patients showed mortality benefit over normal-weighed patients (HR 0.78; 95%CI 0.66-0.92; p=0.003), with only a trend in overweight patients over normal-weighed patients (HR 0.86; 95%CI 0.74-1.00; p=0.05). At multivariate analysis, BMI ‹25 patients showed a 19% higher risk of all-cause mortality compared to overweight and obese patients (HR 1.19; 95%CI 1.03-1.38; p=0.02) after adjusting for age, sex, NYHA class, diabetes, hypertension, myocardial infarction and atrial fibrillation. Obese and overweight patients were younger than normal-weighed patients (68yrs. vs. 69yrs. vs. 70 yrs.; p‹0.0001), similar sex distribution can be seen. Diabetes (BMI ‹25 48% vs. BMI 25-29.9 37% vs. BMI≥30 26%; p‹0.0001) and hypertension (BMI ‹25 82% vs. BMI 25-29.9 74% vs. BMI≥30 71%; p‹0.001) occurred more frequently in obese and overweight patients. Obese and overweight patients had a higher LVEF than in the normal weight group (30% vs. 28% vs. 27%; p‹0.001), respectively. Peri-procedural complication rates did not differ in the three groups. In all patient groups, a significant improvement in LVEF at 6 months was seen (BMI ‹25 ∆-EF 7%, BMI 25-29.9 ∆-EF 7.5%, and BMI ≥30 ∆-EF 6; p<0.001). No difference was seen in the proportion of developing reverse remodeling (BMI ‹25 58% vs. BMI 25-29.9 61% vs. BMI≥30 57%; p=0.75). CONCLUSIONS: Despite having more co-morbidities like diabetes or hypertension, obese patients showed mortality benefit over normal-weighed patients proving, that the obesity paradox was present in our CRT patient cohort at long-term. Peri-procedural complications did not occur more frequently in obese or overweight patients. Echocardiographic response did not vary, similar reverse remodeling was observed across the patient groups.
format Online
Article
Text
id pubmed-10207426
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102074262023-05-25 The risk of obesity and the association of body mass index on all-cause mortality after cardiac resynchronization therapy Merkel, E D Behon, A Schwertner, W R Kuthi, L Veres, B Masszi, R Osztheimer, I Papp, R Molnar, L Zima, E Geller, L Kosztin, A Merkely, B Europace 14.3 - Cardiac Resynchronisation Therapy (CRT) FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public grant(s) – EU funding. Main funding source(s): European Union. BACKGROUND: Overweight and obese people have a higher risk of acquiring heart failure, however these patients tend to have more favorable outcome, a phenomenon known as the obesity paradox. PURPOSE: We aimed to investigate the risk of obesity and the association of body mass index (BMI) on all-cause mortality in heart failure CRT patients at long-term. METHODS: We examined retrospectively 1585 patients undergoing CRT implantation at our clinic between 2000-2020 with their BMI available at baseline. Patients were sorted into three groups: normal weight (BMI ‹25), overweight (BMI 25-29.9) and obese (BMI≥30). The composite primary endpoint was all-cause mortality, heart transplantation or implantation of a left ventricular assist device. Time-to-event data was studied by log-rank and multivariate Cox regression analysis. We studied peri-procedural complication rates, and reverse remodeling, defined as a ≥15% relative increase in left ventricular ejection fraction (LVEF) within 6 months after CRT implantation. RESULTS: During our mean follow-up time of 5.1 years, 973 (61%) reached our primary endpoint, 302 (66%) in the BMI ‹25 group, 389 (61%) in the BMI 25-29.9 group and 282 (58%) in the BMI≥30 group. Obese patients showed mortality benefit over normal-weighed patients (HR 0.78; 95%CI 0.66-0.92; p=0.003), with only a trend in overweight patients over normal-weighed patients (HR 0.86; 95%CI 0.74-1.00; p=0.05). At multivariate analysis, BMI ‹25 patients showed a 19% higher risk of all-cause mortality compared to overweight and obese patients (HR 1.19; 95%CI 1.03-1.38; p=0.02) after adjusting for age, sex, NYHA class, diabetes, hypertension, myocardial infarction and atrial fibrillation. Obese and overweight patients were younger than normal-weighed patients (68yrs. vs. 69yrs. vs. 70 yrs.; p‹0.0001), similar sex distribution can be seen. Diabetes (BMI ‹25 48% vs. BMI 25-29.9 37% vs. BMI≥30 26%; p‹0.0001) and hypertension (BMI ‹25 82% vs. BMI 25-29.9 74% vs. BMI≥30 71%; p‹0.001) occurred more frequently in obese and overweight patients. Obese and overweight patients had a higher LVEF than in the normal weight group (30% vs. 28% vs. 27%; p‹0.001), respectively. Peri-procedural complication rates did not differ in the three groups. In all patient groups, a significant improvement in LVEF at 6 months was seen (BMI ‹25 ∆-EF 7%, BMI 25-29.9 ∆-EF 7.5%, and BMI ≥30 ∆-EF 6; p<0.001). No difference was seen in the proportion of developing reverse remodeling (BMI ‹25 58% vs. BMI 25-29.9 61% vs. BMI≥30 57%; p=0.75). CONCLUSIONS: Despite having more co-morbidities like diabetes or hypertension, obese patients showed mortality benefit over normal-weighed patients proving, that the obesity paradox was present in our CRT patient cohort at long-term. Peri-procedural complications did not occur more frequently in obese or overweight patients. Echocardiographic response did not vary, similar reverse remodeling was observed across the patient groups. Oxford University Press 2023-05-24 /pmc/articles/PMC10207426/ http://dx.doi.org/10.1093/europace/euad122.453 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 14.3 - Cardiac Resynchronisation Therapy (CRT)
Merkel, E D
Behon, A
Schwertner, W R
Kuthi, L
Veres, B
Masszi, R
Osztheimer, I
Papp, R
Molnar, L
Zima, E
Geller, L
Kosztin, A
Merkely, B
The risk of obesity and the association of body mass index on all-cause mortality after cardiac resynchronization therapy
title The risk of obesity and the association of body mass index on all-cause mortality after cardiac resynchronization therapy
title_full The risk of obesity and the association of body mass index on all-cause mortality after cardiac resynchronization therapy
title_fullStr The risk of obesity and the association of body mass index on all-cause mortality after cardiac resynchronization therapy
title_full_unstemmed The risk of obesity and the association of body mass index on all-cause mortality after cardiac resynchronization therapy
title_short The risk of obesity and the association of body mass index on all-cause mortality after cardiac resynchronization therapy
title_sort risk of obesity and the association of body mass index on all-cause mortality after cardiac resynchronization therapy
topic 14.3 - Cardiac Resynchronisation Therapy (CRT)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207426/
http://dx.doi.org/10.1093/europace/euad122.453
work_keys_str_mv AT merkeled theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT behona theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT schwertnerwr theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT kuthil theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT veresb theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT masszir theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT osztheimeri theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT pappr theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT molnarl theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT zimae theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT gellerl theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT kosztina theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT merkelyb theriskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT merkeled riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT behona riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT schwertnerwr riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT kuthil riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT veresb riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT masszir riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT osztheimeri riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT pappr riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT molnarl riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT zimae riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT gellerl riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT kosztina riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy
AT merkelyb riskofobesityandtheassociationofbodymassindexonallcausemortalityaftercardiacresynchronizationtherapy